Posted by Michael Wonder on 08 Jan 2019
Amgen makes all Repatha (evolocumab) device options available in the US at a 60 percent reduced list price
7 January 2019 - The Repatha pre-filled syringe and Repatha Pushtronex system are now available at a reduced list price of $5,850.
Amgen today announced that as part of the Company's commitment to improve patient affordability for an innovative biologic medicine for people with high cholesterol who are at risk for heart attacks and strokes, all Repatha (evolocumab) device options, including the pre-filled syringe and Pushtronex (on-body infusor with pre-filled cartridge), are now available at a 60 percent reduced list price of $5,850 per year.
The most commonly used delivery system, the Repatha SureClick auto-injector, was made available at the lower list price of $5,850 on 24 October 2018. The lower priced Repatha options are identical to the Repatha options currently available, but have been introduced to reduce out-of-pocket costs for patients, especially Medicare patients.
